Hershey Denise Soltow
College of Nursing, Michigan State University, MI, USA.
Asia Pac J Oncol Nurs. 2017 Oct-Dec;4(4):313-318. doi: 10.4103/apjon.apjon_40_17.
Cancer patients with diabetes are at increased risk for developing infections, being hospitalized, and requiring chemotherapy reductions or stoppages. While it has been hypothesized that glycemic control increases the risk for these adverse events, few studies have explored this hypothesis. The purpose of this paper is to discuss the importance of glycemic control in patients with diabetes and cancer during treatment through end of life. Glycemic control was found to play a role; the overall level of health-related quality of life experienced by patients with cancer and diabetes, level of symptom severity experienced and can impact the overall survival of the individual. Evidence-based policies and practice guidelines also need to be developed to help clinicians manage these patients during all phases of care. Using diabetes educators and advance practice, nurses to provide management and care coordination services need to be considered. Survivorship care plans should address both cancer and diabetes management. Finally, glycemic control should continue through end of life, with the main goal of avoiding hypoglycemic events.
患有糖尿病的癌症患者发生感染、住院以及需要减少或停止化疗的风险增加。虽然有假设认为血糖控制会增加这些不良事件的风险，但很少有研究探讨这一假设。本文的目的是讨论从治疗开始到生命结束期间，血糖控制在糖尿病合并癌症患者中的重要性。研究发现血糖控制发挥着作用；癌症合并糖尿病患者所经历的与健康相关的生活质量总体水平、症状严重程度会影响个体的总体生存。还需要制定基于证据的政策和实践指南，以帮助临床医生在护理的各个阶段管理这些患者。应考虑利用糖尿病教育工作者和高级执业护士提供管理和护理协调服务。生存护理计划应兼顾癌症和糖尿病的管理。最后，血糖控制应持续到生命结束，主要目标是避免低血糖事件。
